Aquinox to Present at the 17th Annual Needham Healthcare Conference

Wednesday, March 21, 2018 1:00 PM UTC

VANCOUVER, British Columbia, March 21, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28^th 2018.

Aquinox Presentation Details

Date: Wednesday, March 28^th 2018
Time: 2:00 pm Eastern Time / 11:00 am Pacific Time
Location: New York, NY – Westin New York Grand Central

A live audio webcast and archive of the event will be available at:

http://wsw.com/webcast/needham86/aqxp/

To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.

About Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.

Investor Contact Info:

Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]

Gitanjali Ogawa
Vice President
The Trout Group 
646-378-2949 
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Aquinox to Present at the 17th Annual Needham Healthcare Conference

Editor's Picks

Welcome to EconoTimes